

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/120262/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Mullins, Alex J. , Murray, James A. H. , Bull, Matthew J., Jenner, Matthew, Jones, Cerith , Webster, Gordon , Green, Angharad E., Neill, Daniel R., Connor, Thomas R. , Parkhill, Julian, Challis, Gregory L. and Mahenthiralingam, Eshwar 2019. Genome mining identifies cepacin as a plant-protective metabolite of the biopesticidal bacterium *Burkholderia ambifaria*. *Nature Microbiology* 4 , pp. 996-1005. 10.1038/s41564-019-0383-z

Publishers page: <http://dx.doi.org/10.1038/s41564-019-0383-z>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 **Title:** Genome mining identifies cepacin as a plant-protective metabolite of the biopesticidal bacterium
2 *Burkholderia ambifaria*

3
4 **Short title:** *Burkholderia ambifaria*: Genomics and biology of a biopesticide

5
6 **Authors:**

7 Alex J. Mullins¹, James. A. H. Murray¹, Matthew J. Bull¹, Matthew Jenner², Cerith Jones^{1,6}, Gordon
8 Webster¹, Angharad E. Green³, Daniel R. Neill³, Thomas R. Connor¹, Julian Parkhill⁴, Gregory L.
9 Challis^{2,5} and Eshwar Mahenthiralingam¹

10
11
12 **Author affiliations and footnotes**

13 ¹Microbiomes, Microbes and Informatics Group, Organisms and Environment Division, School of
14 Biosciences, Cardiff University, Cardiff CF10 3AX, United Kingdom

15 ²Department of Chemistry and Warwick Integrative Synthetic Biology Centre, University of Warwick,
16 Coventry CV4 7AL, United Kingdom

17 ³Institute of Infection and Global Health, University of Liverpool, Liverpool L69 7BE, United Kingdom

18 ⁴Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, United
19 Kingdom

20 ⁵Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash
21 University, Clayton, VIC 3800, Australia

22 ⁶Current address: Faculty of Computing, Engineering and Science, University of South Wales,
23 Pontypridd, CF37 1DL, United Kingdom

24
25 **Corresponding author**

26 Submission and handling: Prof. Eshwar Mahenthiralingam, Microbiomes, Microbes and Informatics
27 Group, Organisms and Environment Division, School of Biosciences, Cardiff University, Sir Martin Evans
28 Building, Museum Avenue, Cardiff CF10 3AX, United Kingdom; Tel. +44 (0)29 20875875; Fax. +44
29 (0)29 20874305;

30 Email: MahenthiralingamE@cardiff.ac.uk (ORCID: 0000-0001-9014-3790)

31
32 **Joint correspondence:** Alex J. Mullins, Microbiomes, Microbes and Informatics Group, Organisms and
33 Environment Division, School of Biosciences, Cardiff University, Sir Martin Evans Building, Museum
34 Avenue, Cardiff CF10 3AX, United Kingdom; Tel. +44 (0)29 20874648
35 Email: MullinsA@cardiff.ac.uk (ORCID: 0000-0001-5804-9008)

36
37
38 **Key words:** *Burkholderia*, biopesticides, phylogenomics, genome mining, specialized metabolites

40 **Abstract**

41

42 **Beneficial microorganisms are widely used in agriculture for control of plant pathogens but a**
43 **lack of efficacy and safety information has limited the exploitation of multiple promising**
44 **biopesticides. We applied phylogeny-led genome mining, metabolite analyses and biological**
45 **control assays to define the efficacy of *Burkholderia ambifaria*, a naturally beneficial bacterium**
46 **with proven biocontrol properties, but potential pathogenic risk. A panel of 64 *B. ambifaria***
47 **strains demonstrated significant antimicrobial activity against priority plant pathogens. Genome**
48 **sequencing, specialized metabolite biosynthetic gene cluster mining and metabolite analysis**
49 **revealed an armoury of known and unknown pathways within *B. ambifaria*. The biosynthetic**
50 **gene cluster responsible for the production of the metabolite, cepacin, was identified and**
51 **directly shown to mediate protection of germinating crops against *Pythium* damping-off disease.**
52 ***B. ambifaria* maintained biopesticidal protection and overall fitness in soil after deletion of its**
53 **third replicon, a non-essential plasmid associated with virulence in *B. cepacia* complex bacteria.**
54 **Removal of the third replicon reduced *B. ambifaria* persistence in a murine respiratory infection**
55 **model. Here we show that by using interdisciplinary phylogenomic, metabolomic and functional**
56 **approaches, the mode of action of natural biological control agents related to pathogens can be**
57 **systematically established to facilitate their future exploitation.**

58

59 **Main**

60 Numerous bacterial and fungal species have been recognised for their biological control abilities and
61 plant growth-enhancing properties. Pesticides conventionally used in agriculture are under increasing
62 scrutiny regarding their bioaccumulation and toxicity, which includes their fatal impact on pollinator
63 species. Concern over chemical pesticides has reinvigorated research into biological control agents and
64 their secreted bioactive compounds as viable natural alternatives for agriculture. One feature common to
65 most biopesticidal species is their ability to secrete antimicrobial compounds into the environment and
66 inhibit pathogenic microbes from causing crop disease. Bacteria within the genus *Burkholderia* are
67 particularly diverse in their specialized metabolism and have a documented ability to produce a range of
68 potent anti-bacterial, anti-nematodal and anti-fungal compounds^{1,2}. They have demonstrated excellent
69 promise as biological control agents with multiple strains used commercially as biopesticides until 1999.
70 In common with other biological control genera such as *Bacillus*, *Pseudomonas* and *Stenotrophomonas*,
71 certain *Burkholderia* species may also cause human, animal and plant infections. Therefore, in 1999 the
72 US Environmental Protection Agency (EPA) placed a moratorium on new registrations of *Burkholderia*
73 biopesticides unless such agents were defined as safe in terms of their risk of opportunistic infection².

74

75 Multiple species within the *Burkholderia cepacia* complex group were characterised or used as biological
76 control agents². They are highly active in their specialized metabolism, for example, producing antifungal
77 compounds including pyrrolnitrin, occidiofungin, cepafungin and burkholdines; antibacterial bactobolins

78 and enacyloxin IIa; and broader spectrum agents such as the cepacins^{3,4}. Outside of the *B. cepacia*
79 complex, other *Burkholderia* species also produce a range of antagonistic compounds. The bactobolins
80 are also produced by *Burkholderia thailandensis* and *Burkholderia pseudomallei* and exhibit potent
81 activity against Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus*⁵.
82 *Burkholderia gladioli* also produces multiple antimicrobials including the anti-mycobacterial macrolide
83 gladiolin⁶, its isomer lagriene⁷, the cytotoxic azapteridine toxoflavin⁸, and the polyene caryoynencin⁹.
84 There is no consensus on the distribution or co-occurrence of antimicrobial specialized metabolite
85 encoding gene clusters in biopesticidal *B. ambifaria*, nor a holistic understanding of strain bioactivity and
86 antimicrobial compound efficacy against priority bacterial^{10,11}, fungal and oomycetal plant pathogens².
87 Biopesticidal activities have been descriptively characterised for individual producer strains against a
88 panel of target organisms, or multiple producer strains against relatively few target organisms². Previous
89 studies have analysed the overall antagonistic properties of *B. ambifaria*, but none have examined the
90 role of specific antimicrobial compounds in mediating biocontrol in natural soil microcosm models.

91
92 To establish a biotechnological platform for biopesticidal use of *B. ambifaria* that considers its efficacy
93 and safety, we systematically defined the genomic basis and functional efficacy of antimicrobial
94 metabolites in 64 strains including 8 previously characterised biocontrol strains (Supplementary Table
95 1). The strain collection examined included 58 environmental isolates recovered from multiple sources
96 (soil, the maize, pea and grass rhizosphere, and leaves) and 6 strains isolated from the sputum of
97 people with cystic fibrosis (CF). Collectively, it also represented strains recovered from various
98 geographic origins (USA, Australia and Italy; Supplementary Table 1). The *B. ambifaria* core and
99 accessory genome was revealed, and gene cluster network analyses were combined with antimicrobial
100 activity assays to rationally understand the biopesticidal activity against crop pathogens. The role of
101 individual antimicrobial metabolites in mediating crop protection was investigated using biosynthetic
102 pathway mutants in non-sterile soil biocontrol models. Since curing of the *B. cepacia* complex third
103 genomic replicon (c3) is possible in these multireplicon bacteria¹², a *B. ambifaria* c3 mutant was
104 constructed and shown to have reduced virulence in a murine respiratory infection model, yet retained
105 its plant-protective properties. This work provides a foundation for developing targeted biological control
106 agents and effective biocontrol products for reducing agricultural crop losses from bacterial, fungal and
107 oomycete pathogens.

108 109 **Results:**

110 ***B. ambifaria* genomics and *in silico* definition of specialized metabolite biosynthetic gene** 111 **clusters**

112 To understand the genome-encoded potential of *B. ambifaria* as a biopesticide, phylogenomic and pan-
113 genomic analyses were applied (see Methods, Supplementary Figure 1, Supplementary Table 2 and
114 Supplementary Notes). The three replicon genomic structure was present in 63 of the *B. ambifaria*
115 strains analysed, while strain BCC1105 naturally lacked the third replicon. Contigs were scaffolded to
116 one of three reference genomes to assemble complete genomes. The assembled genome sizes varied

117 across the 64 strains, from 6.13 Mbp (BCC1105) to 8.03 Mbp (BCC1248), with a mean of 7.34 Mbp
118 (Supplementary Table 2). Assembled replicons c1, c2 and c3 possessed a mean of 3.47 Mbp, 2.74 Mbp
119 and 1.15 Mbp, respectively. Replicon c3 possessed the greatest variation in sequence capacity,
120 whereas replicons c2 and c1 displayed greater consistency in size (Supplementary Table 2). A large *B.*
121 *ambifaria* pan-genome was identified (22,376 distinct genes) of which 3784 genes comprised the core
122 genome. The pan-genome represented a collection of genes approximately 3.4-fold greater than the
123 mean *B. ambifaria* genome (6,546 genes). A large proportion of the accessory genome, 78.1% (14,582
124 genes), was shared by less than 15% of the *B. ambifaria* strains. Exclusion of the strain which lacked the
125 third replicon, BCC1105, from the core genome analysis resulted in the *B. ambifaria* core genome
126 increasing from 3784 to 4166 genes. Three major clades were identified in the *B. ambifaria* 3784 core-
127 gene phylogeny (Figure 1A), and this established the evolutionary framework onto which the
128 antimicrobial properties of each strain were overlaid using *in silico* and bioactivity approaches. *In silico*
129 analyses of the 64 *B. ambifaria* genomes (see Methods, Supplementary Table 3 and Supplementary
130 Notes) detected 1272 specialized metabolite biosynthetic gene clusters (BGCs), that were de-replicated
131 into 38 distinct BGCs after Kmer-matching and gene topology comparisons (Figure 2; Supplementary
132 Table 3). Network analysis was used to graphically summarise multiple attributes of the *B. ambifaria*
133 BGCs including their biosynthetic diversity, strain distribution, and core or accessory nature within the
134 species (Figure 2).

135
136 Of the 38 distinct BGCs, 13 were previously characterised, and seven known to encode compounds with
137 antimicrobial activity (Supplementary Table 4). Pyrrolnitrin¹³ was the only BGC for an antimicrobial
138 metabolite found in all 64 *B. ambifaria* strains, whereas the BGC for the anti-Gram-negative metabolite
139 enacyloxin IIa³ was the least common known antimicrobial BGC (Figure 2). Pyrrolnitrin and phenazine
140 BGCs were encoded on replicon c2 and the remaining antagonistic compounds were encoded by BGCs
141 on replicon c3. No known antimicrobial BGCs were identified on replicon c1. Barring a few exceptions,
142 multiple antimicrobial encoding BGCs were associated with distinct clades within the *B. ambifaria* core-
143 gene phylogeny (Figure 1). Six of the seven clade 1b strains encoded the pathway responsible for
144 enacyloxin IIa biosynthesis³. The more widely distributed burkholdine¹⁴ BGC was absent from all
145 members of clade 2 and strain BCC1105, but all other strains possessed the anti-fungal biosynthetic
146 locus. Bactobolin⁵ BGCs were concentrated in clade 1 and less frequently encountered in clade 2 and 3
147 strains. Two strains, BCC1105 and BCC1224, only encoded the core anti-fungal metabolite pyrrolnitrin,
148 and lacked any additional antimicrobial BGCs (Figure 1B). No single strain encoded all 7 previously
149 known antimicrobial BGCs, however, approximately 59% of strains encoded four or more BGCs
150 reflecting the known antimicrobial properties of *B. ambifaria* (Figure 1B).

151
152 The silent nature of certain antimicrobial BGCs which are not expressed in standard laboratory cultures,
153 including those in *Burkholderia*, is well established^{3,4}. We therefore correlated *in vitro* metabolite
154 production with BGC distribution. Ten *B. ambifaria* strains representing the seven characterised
155 biocontrol strains and three additional strains from the broader species phylogeny (Figure 1A) were

156 screened for metabolite production on agar growth media BSM-G^{3,15}. Six known antimicrobial
157 metabolites were detected by LC-MS (Supplementary Figure 2 and 3), five of which could be directly
158 correlated to the presence of predicted BGCs (Table 1). Under these screening conditions the majority
159 of BGCs (22 of 25) were biosynthetically active and produced the corresponding metabolite; individual
160 strains encoding pyrrolnitrin, burkholdines and hydroxyquinolines BGCs were exceptions to this trend
161 (Table 1). A sixth known metabolite, cepacin A¹⁶, was also detected in *B. ambifaria* J82 (BCC0191) by
162 analytical analyses (see Methods) and subsequently correlated to a BGC (not recognised by antiSMASH
163 v3)¹⁷ identified by searching for quorum sensing (QS) regulated BGCs (see below).

164

165 **Mapping direct antimicrobial activity against plant and animal pathogens**

166 Having established the presence of BGCs (Figures 1b and 2) and corresponding metabolites (Table 1),
167 antagonism activity of the 64 *B. ambifaria* strains against priority plant¹⁰ and human pathogens
168 (Supplementary Table 5) was evaluated as described³. The *in vitro* bioactivity was aligned against the
169 core-gene phylogeny to map antagonism across *B. ambifaria* as a species (Figure 1c). A total of six
170 strains lacked observable antimicrobial activity (Figure 1c). Clade 1a, 1b and 1c strains exhibited
171 substantial bioactivity against Gram-negative pathogens, while only two strains outside these clades
172 exhibited similar activity (Figure 1c). Clade 1b strains exhibited additional strong antagonistic activity
173 towards Betaproteobacteria, *Burkholderia multivorans* and Alphaproteobacteria, *Rhizobium radiobacter*
174 (Figure 1c), an activity not observed in other anti-Gram-negative *B. ambifaria* strains. The extended
175 antimicrobial antagonism of clade 1b *B. ambifaria* correlated to the presence of the *trans*-AT PKS BGC
176 for enacyloxin IIa (Figure 1b); all screened Gram-negative pathogens were susceptible to purified
177 enacyloxin IIa with MICs ranging from 3.2 to 50 µg/ml (Supplementary Table 6). The additional anti-
178 Gram-negative activity correlated to the presence of the hybrid NRPS-PKS encoding BGC for bactobolin
179 (Figure 1b). Anti-fungal (against *Candida albicans*, *Fusarium solani* and *Alternaria alternata*) and anti-
180 Gram-positive (against *Staphylococcus aureus*, *Enterococcus faecalis* and *Bacillus subtilis*) activity was
181 more widespread than anti-Gram-negative activity in *B. ambifaria*, with 82% and 69% of tested strains
182 (62 of 64) exhibiting these activities, respectively (Figure 1). Clade 2 *B. ambifaria* strains exhibited the
183 least antimicrobial activity (5 of 9 lacking any *in vitro* observable activity) despite encoding BGCs for
184 pyrrolnitrin, hydroxyquinolines, and cepacin (Figure 1b).

185

186 **A search for QS-regulated BGCs reveals the biosynthetic locus for the potent anti-oomycetal** 187 **cepacin**

188 Multiple specialized metabolite BGCs are QS controlled^{3,4} and manipulation of this regulatory system
189 has also been harnessed for *Burkholderia* metabolite discovery¹⁸. A search of *luxR* homologues within
190 the *B. ambifaria* genomes was performed (see Supplementary Notes) and downstream of an
191 uncharacterised LuxRI system (encoded by 22 of 64 strains) (Figure 3) was a conspicuous BGC
192 encoding fatty acid desaturases, a beta-ketoacyl synthase and an acyl carrier protein (Figure 4a).
193 Insertional mutagenesis of a fatty acyl-adenosine monophosphate (AMP) ligase-encoding gene, *ccnJ*,
194 within this BCG was carried out in six *B. ambifaria* strain backgrounds (BCC0191, BCC1252, BCC1241,

195 BCC0477, BCC1259 and BCC1218; Figure 1). The resulting mutants lacked anti-Gram-positive activity
196 and the weak anti-Gram-negative activity, and showed considerably diminished growth inhibition of the
197 oomycete *Pythium ultimum* (Figure 4b and Supplementary Figure 4). High resolution mass spectrometry
198 of metabolite extracts from strain BCC0191 identified ions with $m/z = 271.0964$, corresponding to a
199 predicted molecular formula of $C_{16}H_{14}O_4$ consistent with cepacin A, a historically described *Burkholderia*
200 polyynes¹⁶ of un-defined biosynthetic origin. Direct comparison with extracts from the originally reported
201 cepacin A and cepacin B producer strain, "*B. cepacia*" ATCC 39356¹⁶ (taxonomically reclassified as a
202 *Burkholderia diffusa* strain), confirmed that *B. ambifaria* BCC0191 produces cepacin A (Supplementary
203 Figure 5). Cepacin A was absent in the *B. ambifaria* BCC0191::*ccnJ* cepacin insertional mutant (Figure
204 4c), confirming that the uncharacterised LuxRI-associated BGC was responsible for the biosynthesis of
205 this known *Burkholderia* metabolite. The cepacin A BGC is located on the second replicon of 22 *B.*
206 *ambifaria* strains, with 100% and 56% presence in clade 3 and clade 2 strains, respectively (Figure 1b).

207

208 **Cepacin A is a key mediator of *B. ambifaria* biocontrol of *Pythium ultimum* damping-off disease**

209 *B. ambifaria* has been observed to inhibit *P. ultimum* and application to prevent crop damping-off
210 diseases was a key trait in its historical biopesticide use². However, the metabolites and/or BGCs which
211 drive *Burkholderia* crop protection against *Pythium*-mediated damping-off have not been defined in a
212 relevant biopesticide model, such as bacterial seed coating and planting in pathogen infested soil². The
213 cepacin-producer *B. ambifaria* BCC0191 exhibited strong biopesticidal activity when introduced as a *P.*
214 *sativum* (pea) seed-coat to a *P. ultimum* biocontrol model in non-sterile soil (Figure 5a). Disruption of the
215 cepacin BGC and application of the BCC0191 cepacin mutant as a seed coat reduced pea plant survival
216 rates by more than 60% dependent on *B. ambifaria* seed coat inoculum level (10^5 , 10^6 and 10^7 cfu/seed;
217 Figure 5a). No biological control was observed when 10^5 cfu/seed of BCC0191 cepacin mutant was
218 applied (<10% survival), compared to >50% protection mediated by the wild type at this level (Figure
219 5a).

220

221 A unique feature of the *B. cepacia* complex multi-replicon genome is that the third replicon is not
222 essential and c3 deletion mutants lose virulence and antifungal phenotypes¹². The cepacin BGC is
223 located on the second c2 replicon of *B. ambifaria* and its biosynthesis was maintained when a third
224 replicon deletion mutant, BCC0191 Δ c3, was constructed. Despite the loss of >1 Mb of DNA, the
225 BCC0191 Δ c3 derivative remained competitive and biopesticidal in the *Pythium*-infested soil microbial
226 community, protecting peas from damping-off at a rate marginally below that of the wild type (Figure 5b;
227 the difference was not significant for a given inoculation size). The phenotypes of *B. ambifaria* BCC0191,
228 its cepacin-deficient derivative (::c*ccnJ*), c3 knockout mutant (Δ c3), and combined cepacin-c3 mutation
229 (::c*ccnJ* Δ c3) were tested further to understand the wider effect of these mutations on strain fitness (see
230 Supplementary Notes). Antimicrobial activity against Gram-positive bacteria and *Pythium* was lost in the
231 cepacin deficient mutant (Supplementary Figure 6). The BCC0191 c3 mutant lost antifungal activity but
232 had a 2-fold increase in cepacin production enhancing its anti-Gram-positive antagonism
233 (Supplementary Figure 6). Rhizocompetence was similar for the BCC0191 WT and BCC0191::*ccnJ*, but

234 the third replicon deletion mutant colonised the pea rhizosphere at a significantly lower rate of 8.5×10^6
235 cfu/g root ($p = 0.027$; Supplementary Table 7).

236

237 A lack of understanding of safety and human pathogenicity were key reasons the US EPA placed a
238 moratorium on *B. cepacia* complex biopesticides². Since the BCC0191 Δ c3 mutant had retained its
239 biopesticidal ability (Figure 5b), yet loss of this replicon is associated with reduced virulence in multiple
240 infection models¹², we assessed the pathogenicity of *B. ambifaria* BCC0191 and its c3 deletion mutant.
241 In the *Galleria mellonella* wax-moth larvae model¹², the deletion of the third replicon did not attenuate the
242 virulence (Supplementary Figure 7a), showing that genes encoding significant insecticidal pathogenicity
243 were not encoded on c3 in *B. ambifaria* strain BCC0191. In contrast, using a murine respiratory infection
244 model relevant to chronic cystic fibrosis lung infections^{19,20}, the persistence of *B. ambifaria* BCC0191
245 was low and loss of the third replicon BCC0191 Δ c3 further reduced persistence in the lung
246 (Supplementary Figure 7b and Supplementary Figure 7c). At an infective dose of 2×10^6 bacteria, the
247 BCC0191 wild type persisted in the nasopharynx for the duration of the 5-day experiment but was
248 cleared from lungs of 4 out of 6 mice by day 5. In contrast, the c3 mutant was rapidly cleared from both
249 nasopharynx and lungs of mice (Supplementary Figure 8). Low numbers of the parental BCC0191 strain
250 (<50 colonies) were detected in the lungs of mice after 5 days of infection, but BCC0191 Δ c3 was
251 cleared within 48 hours. *B. ambifaria* (wild-type or c3 mutant) was not detected within the spleens of
252 infected mice and no visible disease signs were observed throughout. Genotyping by PCR
253 demonstrated that the low numbers of colonies recovered from the mouse infection model were either
254 the administered *B. ambifaria* BCC0191 or BCC0191 Δ c3, respectively (Supplementary Figure 8).

255

256 **Discussion:**

257 Harnessing the potential of naturally biopesticidal bacteria is an important consideration if we are to keep
258 pace with agricultural intensification and global food security. With increasing regulatory and
259 environmental scrutiny of pesticides, the properties of natural agents will also have to be systematically
260 defined before widespread use. Our in-depth genomic analysis of the *intra*-species diversity of *B.*
261 *ambifaria* as a biopesticide and direct linkage of its specific metabolite, cepacin, to antagonism of
262 *Pythium* and prevention of crop damping-off disease, sets a precedent on the mode of action of
263 *Burkholderia* biopesticides. We have developed a holistic understanding of biopesticidal *B. ambifaria*,
264 determining their pan-genomic content, extensive library of antimicrobial BGCs, efficacy in targeting key
265 plant pathogens with specific antimicrobial metabolites, and defining the population biology of historically
266 applied *B. ambifaria* biopesticides (see Supplementary Discussion). We have shown that biological
267 control of damping-off disease in a relevant soil model is critically mediated by cepacin A, encoded on
268 the second replicon of *B. ambifaria*. Since effective biological control of *Pythium* also occurs in the
269 absence of the third replicon, which has been characterised as a *Burkholderia* virulence plasmid¹², we
270 have highlighted this as an attenuation strategy for developing potentially safe biopesticide strains which
271 retain biotechnological efficacy.

272

273 **Discovery of cepacin biosynthetic gene cluster**

274 Mining and phylogenetically clustering the LuxR protein sequences from 64 *B. ambifaria* genomes
275 revealed multiple solo and *luxI*-associated *luxR* genes, and these were linked with both known and
276 uncharacterised specialised metabolite BGCs. In addition to the *B. ambifaria* encoded enacyloxin³ and
277 bactobolin⁵ BGCs, LuxR regulation of other specialised metabolite BGCs has been further described
278 within and outside the genus. *Burkholderia thailandensis* synthesises the quorum sensing regulated
279 cytotoxic compound malleilactone²¹, and pyocyanin production in *Pseudomonas aeruginosa* is controlled
280 by a hierarchical QS network²². This approach was initially intended to understand the role of quorum
281 sensing regulation in *B. ambifaria* biopesticidal specialised metabolism, but serendipitously led to the
282 identification of the cepacin A BGC.

283

284 Cepacins A and B were initially described as metabolites of *Burkholderia cepacia*, formally
285 *Pseudomonas cepacia*^{16,23}, with the original producer strain now classified as *B. diffusa*²⁴. Both polyne
286 metabolites displayed strong anti-*Staphylococci* activity, while cepacin A showed weak anti-Gram-
287 negative activity¹⁶. Cluster K, a gene cluster with 76.9% homologous nucleotide similarity spanning 12.9
288 kbp (in addition to 8.4 kbp of non-homologous regions) to the *B. ambifaria* cepacin A BGC was identified
289 in *Collimonas fungivorans* Ter331 using nucleotide BLAST (Supplementary Figure 9). The *C.*
290 *fungivorans* cluster K has been linked to the biosynthesis of the anti-fungal polyne collimomycin²⁵
291 whose BGC organisation (Supplementary Figure 9) and chemical formula (C₁₆H₁₈O₄) resemble cepacin
292 A (C₁₆H₁₄O₄). Recent characterisation of this *C. fungivorans* strain showed it produces a range of
293 polyynes, collectively designated the collimonins²⁶, with collimonin A showing the most structural
294 similarity to cepacin A. Several key differences in gene content were identified between the cepacin and
295 collimonin BGCs in the regions flanking the core biosynthetic genes (Supplementary Figure 9). *C.*
296 *fungivorans* cluster K contains genes encoding four additional hypothetical proteins, a major-facilitator
297 superfamily transporter and fatty acid desaturase; whereas the *B. ambifaria* cepacin BGC encoded one
298 extra hypothetical protein. An unusual feature of the cepacin and collimonin BGC variants is the
299 substitution of the associated regulatory genes that comprise a QS-associated *luxRI* in *Burkholderia* and
300 a *lysR* regulator in *Collimonas* (Supplementary Figure 9). Similar proteins to those identified in the
301 cepacin BGC are listed in Supplementary Table 8.

302

303 **Cepacin A is a major component of *B. ambifaria* biological control**

304 We have demonstrated the importance of cepacin A in the context of biological control of the major crop
305 family Fabaceae (*Pisum sativum*). Disruption of the cepacin BGC in *B. ambifaria* significantly reduced
306 plant survival beyond germination and emergence compared to the wild-type (Figure 5a; p < 0.05). The
307 contribution of specific metabolites to biocontrol has been studied extensively in *Pseudomonas*²⁷
308 relative to other characterised biocontrol genera. The anti-fungal properties of pyrrolnitrin and 2,4-
309 diacetylphloroglucinol have been evidenced as important metabolites in the biological control of several
310 fungal pathogens, on a diversity of crops, in a range of *Pseudomonas* species and strain backgrounds²⁷.

311 Other studies have highlighted the *in vitro* antimicrobial activity, and presence of the corresponding
312 specialized metabolite BGCs or protective effects in field trials in *Bacillus*²⁸ and *Streptomyces*²⁹, but fail
313 to define the impact of distinct metabolites in a biocontrol system. This study establishes the role of
314 cepacin A as the major bioactive component of the *B. ambifaria* armoury in the biocontrol of damping-off
315 disease by *P. ultimum* in a relevant non-sterile soil model. The reduced protection against *P. ultimum* of
316 the cepacin A-deficient mutant compared to the wild-type *B. ambifaria* also indirectly confirms the
317 expression of the cepacin A BGC *in planta* (Figure 5b).

318
319 There has been considerable discussion on whether *Burkholderia* species known to cause opportunistic
320 infections can be safely exploited for environmental benefit³⁰. Multiple species in the recently defined
321 *Paraburkholderia* genus have not been associated with infection, are generally environmental, and
322 mediate plant-beneficial interactions³⁰. Transfer of biopesticidal properties such as the *B. ambifaria*
323 cepacin BGC to *Paraburkholderia* species is a potential route to future safe usage. Attenuation of
324 pathogenicity in biopesticidal strains is an alternative means to facilitate their biotechnological
325 exploitation. Third replicon deletion in *B. ambifaria* BCC0191 led to loss of persistence in the murine lung
326 infection model (Supplementary Figure 7b and 7c), and hence provides an unmarked means of
327 attenuating pathogenicity but preserving biopesticidal potential in this strain (see Supplementary
328 Discussion, Figure 5). In addition, the BCC0191Δc3 mutant also showed a reduced root colonisation
329 after 14 days compared to the wild type (see Supplementary Discussion, Supplementary Table 7),
330 suggesting it has less potential for bioaccumulation, which is another desirable trait for a biopesticide.
331 Whether c3 deletion is sufficient to render *B. ambifaria* as a species completely avirulent remains to be
332 fully determined. *B. ambifaria* is rarely found in CF lung infections, with a survey of US patients from
333 1997 to 2007 implicating it collectively with several other *B. cepacia* complex species as causing <3% of
334 all *Burkholderia* cases³¹. A 2017 survey of *Burkholderia* infections in 361 UK CF patients did not find *B.*
335 *ambifaria* at all³². This epidemiological data combined with the low murine respiratory persistence of *B.*
336 *ambifaria* (Supplementary Figure 7b and Supplementary Figure 7c) compared to virulent pathogens
337 such as *P. aeruginosa*^{19,20}, suggests that *B. ambifaria* has low pathogenicity. From this start point,
338 attenuation of virulence using unmarked c3 deletion as performed herein, combined with further
339 essential gene mutation strategies as used to construct live bacterial vaccines, could also provide a
340 route towards the development of safe *B. ambifaria* biopesticides.

341

342 **Conclusion:**

343 Biological control agents have been applied to crops with success in the past, but no in-depth genomic
344 or analytical chemistry analyses have been conducted on individual species to assess their biocontrol
345 potential. This study demonstrated the benefits of using genome mining and *in vitro* antimicrobial
346 screening to define BGCs that contribute to biocontrol, and enable their use in the rational design of
347 future bacterial biopesticides. The potential of cepacin-producing *B. ambifaria* in protecting economically
348 relevant crop species from attack by oomycete pathogens has been demonstrated. It is clear that *B.*

349 *ambifaria* has accumulated multiple plant protective BGCs that underpin its historical exploitation as a
350 biopesticide². With an urgent need to sustain crop protection and agricultural production, yet reduce use
351 of environmentally persistent chemical pesticides, systematically repurposing natural biological control
352 agents such as *B. ambifaria* for biotechnology is a timely alternative solution.

353

354 **Methods:**

355

356 **Genome sequencing and replicon assembly**

357 Genomes used in this study were either sequenced as part of this study or downloaded from public
358 databases. 125-nucleotide and 150-nucleotide paired-end reads were generated for 60 *B. ambifaria*
359 genomes (Supplementary Table 1) using an Illumina HiSeq 2000 and HiSeq X Ten, respectively.
360 Illumina adaptors were trimmed, read quality assessed and contigs assembled as described in the
361 Supplementary Notes. Genomic contigs were re-arranged and scaffolded into replicons by mapping the
362 contigs against three reference genomes using CONTIGuator v2.7.4³³. The option to fill gaps using
363 strings of “N” was disabled. Reference genomes were *B. ambifaria* AMMD (SAMN02598309) and *B.*
364 *ambifaria* MC40-6 (SAMN02598385), both obtained from the European Nucleotide Archive; the third
365 reference, *B. ambifaria* BCC0203, was generated using Pacific Biosciences single molecule real time
366 sequencing. The replicons were manually assessed for any scaffolding errors and corrected when
367 necessary. Completed replicons (c1, c2 and c3) were re-circularised based on genes *dnaA*, *parA* and
368 *parB*, respectively, using the software Circlator v1.2.1³⁴. The species validity of *B. ambifaria* dataset was
369 defined by calculating the average nucleotide identity (ANI) shared between all available *B. ambifaria*
370 genomes using PyANI v0.2.1³⁵. Two sequenced strains from this study (BCC1630 and BCC1638) and
371 one publically available strain (RZ2MS16) were excluded from the dataset, using a 95% ANI species
372 threshold³⁶. The remaining 64 *B. ambifaria* strains along with mutant derivatives used in this study are
373 listed in the supplementary data (Supplementary Table 1).

374

375 **Genome mining and specialized metabolite BGC network analysis**

376 All bioinformatics analyses were performed using the Cloud Infrastructure for Microbial Bioinformatics
377 (CLIMB) computing resource³⁷. Scaffolded replicons and non-scaffolded contigs were annotated using
378 Prokka v1.12-beta³⁸. Bioinformatics tool antiSMASH v.3.0.5¹⁷ detected specialized metabolite BGCs in
379 both scaffolded and non-scaffolded contig sequences. Known pathways that were not detected by
380 antiSMASH were identified with nucleotide-nucleotide BLAST v2.6.0+³⁹. BGCs were dereplicated by
381 clustering nucleotide sequences using pairwise Kmer-matching software Mash v1.1.1⁴⁰; reporting a
382 maximum p-value and maximum distance of 1 and 0.05, respectively. The resulting distance matrix was
383 visualized with Cytoscape v3.4.0⁴¹, applying the Jaccard index, p-value and Mash distance (estimated
384 mutation rate between sequences) as edge attributes. Duplicated edges between nodes and self-loops
385 were removed from the network analysis. The resulting cluster network was further refined by comparing

386 the gene topologies of pathway representatives from network clusters of the same specialized
387 metabolite class; and splitting or merging network clusters where necessary.

388

389 **Genomic analysis and phylogenomics**

390 The core and accessory genome of the collective 64 *B. ambifaria* strains was calculated using Roary
391 v3.7.0⁴² using a 95% minimum percentage identity for blastp, and core gene threshold of 99%
392 occurrence across the 64 strains. The core gene alignment generated by Roary was used to construct
393 an approximate-maximum-likelihood core-gene phylogeny with double-precision FastTree v2.1.9⁴³. The
394 root position was determined by including the outgroup species *Burkholderia vietnamiensis* G4
395 (PRJNA10696) (Supplementary Figure 10). Once the root branch point was defined, a second tree was
396 constructed using RAxML v8.2.11⁴⁴ with General Time Reversible (GTR) substitution and a GAMMA
397 model of rate heterogeneity supported by 100 bootstraps.

398

399 **Culture conditions and antimicrobial activity screens**

400 All *B. ambifaria* strains were grown in tryptic soy broth (TSB) at 37°C and aerated overnight, unless
401 stated otherwise. The 64 *B. ambifaria* strains were screened for production of antimicrobials with
402 antagonistic activity against 14 plant, animal and human pathogens, and other reference species
403 (Supplementary Table 5). A standard overlay assay was used to screen for antimicrobial activity, as
404 previously described³, with the amendment of using 400 µl overnight (O/N) culture of the susceptibility-
405 testing organism per 100 ml half-strength iso-sensitest agar. A strain was considered antagonistic if the
406 zone of inhibition was >10 mm in diameter. Antagonism assays with *A. alternata* and *F. solani* involved
407 the re-suspension of mycelia in 1 ml PBS from 9-day old cultures grown in 50 mm petri dishes on potato
408 dextrose agar; 320 µl of mycelial resuspension was used per 100 ml half-strength iso-sensitest agar
409 before pouring as an overlay. 10x10 cm square Petri dishes containing basal salts medium¹⁵
410 supplemented with 4 g/l glycerol (BSM-G)³ were used to screen six isolates concomitantly, and a
411 replicator used to transfer the bacterial culture onto the agar surface from 96-well plates. *B. ambifaria*
412 strains were grown on BSM-G for three days at 30°C. Each 96-well plate stored six strains tested for
413 antimicrobial activity, with 200 µl O/N culture grown in TSB broth (Oxoid) per used well, and DMSO at a
414 final concentration of 8% for -80°C storage. Following chloroform-killing, approximately 25 ml of
415 antimicrobial susceptibility test organism-seeded half-strength iso-sensitest agar was poured over each
416 10x10 cm square Petri dish. The plates were incubated at the optimum temperatures of each
417 susceptibility-test organism (Supplementary Table 5). The heatmap of pathogen antagonism was
418 created in statistics software R v3.2.3 via RStudio v0.99.484.

419

420 **Confirmation of the *Burkholderia cepacin* A BGC-metabolite link**

421 Insertional mutagenesis was used to disrupt the expression of the cepacin A pathway. Primers were
422 designed to amplify a 649 bp region of the fatty AMP ligase-encoding gene (Supplementary Table 9),
423 yielding a final product of 707 bp. The product was amplified using the Taq PCR Master Mix Kit
424 (Qiagen), and ligated into the suicide vector pGp-omega-Tp⁴⁵ following restriction with *Xba*I and *Eco*R

425 (NEB). The resulting construct was transformed into competent *Escherichia coli* SY327 via heat-shock
426 (maintained by trimethoprim selection; 50 µg/ml), and subsequently introduced into *B. ambifaria* via tri-
427 parental mating with *E. coli* HB101 carrying the helper plasmid pRK2013 (kanamycin selection, 50
428 µg/ml). The transconjugants were selected using trimethoprim 150 µg/ml and polymyxin 600 U/ml. The
429 presence and correct location of the insertional vector was confirmed by PCR. Comparative-HPLC and
430 antimicrobial activity screens between the wild-type and insertional mutant confirmed the disruption of
431 the cepacin BGC.

432

433 **Construction and phenotypic analysis of a *B. ambifaria* BCC0191Δc3 mutant**

434 The *B. ambifaria* BCC0191Δc3 mutant was constructed following the methods outlined in Agnoli *et al.*
435 2012¹². This involved using the pMiniC3 vector, a 12.6 kb plasmid constructed from the origin of
436 replication of the *B. cenocepacia* H111 third replicon and containing its *repA*, *parB*, and *parA* genes, and
437 trimethoprim resistance and sucrose counter selection cassettes¹². In brief, the pMiniC3 vector was
438 mated into the BCC0191 wild-type to displace the native c3 replicon via a tri-parental mating involving
439 the donor *E. coli* MC1061 pMiniC3, recipient *B. ambifaria* BCC0191 and *E. coli* HB101 carrying the
440 helper plasmid pRK2013. *B. ambifaria* BCC0191 pMinic3 clones were subsequently cured of pMinic3 by
441 sucrose counter-selection. *B. ambifaria* BCC0191Δc3 clones were screened for the absence of both
442 replicon c3 and plasmid pMinic3 by PCR using the DreamTaq Green PCR Master Mix (2X) (Thermo
443 Scientific) (Supplementary Table 9). The virulence of *B. ambifaria* BCC0191 and its Δc3 mutant was
444 evaluated in *G. mellonella* wax moth larvae¹² and murine chronic lung^{19,20} infection models as described
445 below.

446

447 **Detection of LuxR homologues as specialized metabolite regulators**

448 LuxR-encoding gene homologues were identified by replicating the systematic *in silico* approach
449 previously described⁴⁶. In brief, a Hidden Markov Model was built to identify potential LuxR-encoding
450 genes; and these candidates were annotated for encoded protein domains. Candidate genes were
451 considered LuxR-encoding if all four conserved LuxR protein domains were detected. The extracted
452 amino acid sequences were aligned using MAFFT v7.305b⁴⁷ and a phylogenetic tree generated using
453 FastTree v2.1.9⁴³. The regulatory function of the *luxR* gene was inferred either from the literature or
454 genes with putative functions starting within 5 kbp upstream and downstream of the *luxR* gene.

455

456 **Culture conditions, extraction protocol and high resolution mass spectrometry**

457 All *B. ambifaria* strains were grown at 30°C on BSM-G. The original cepacin producer, strain ATCC
458 395396, was obtained from the Belgium Coordinated Collection of Microorganisms where it is deposited
459 as *B. diffusa* strain LMG 24093. Single plates were extracted by addition of 4 ml of acetonitrile for 2
460 hours, followed by centrifugation to remove debris. Crude extracts were directly analysed by UHPLC-
461 ESI-Q-TOF-MS. UHPLC-ESI-Q-TOF-MS analyses were performed using a Dionex UltiMate 3000
462 UHPLC connected to a Zorbax Eclipse Plus C-18 column (100 × 2.1 mm, 1.8 µm) coupled to a Bruker
463 MaXis II mass spectrometer. Mobile phases consisted of water (A) and acetonitrile (B), each

464 supplemented with 0.1% formic acid. A gradient of 5% B to 100% B over 30 minutes was employed at a
465 flow rate of 0.2 ml/min. The mass spectrometer was operated in positive ion mode with a scan range of
466 50-3000 m/z. Source conditions were: end plate offset at -500 V; capillary at -4500 V; nebulizer gas
467 (N₂) at 1.6 bar; dry gas (N₂) at 8 L min⁻¹; dry temperature at 180 °C. Ion transfer conditions were: ion
468 funnel RF at 200 Vpp; multiple RF at 200 Vpp; quadrupole low mass at 55 m/z; collision energy at 5.0
469 eV; collision RF at 600 Vpp; ion cooler RF at 50–350 Vpp; transfer time at 121 μs; pre-pulse storage
470 time at 1 μs. Calibration was performed with 1 mM sodium formate through a loop injection of 20 μL at
471 the start of each run.

472

473 **Biocontrol of *Pythium ultimum* using a *Pisum sativum* model**

474 The infestation of soil with *Pythium ultimum* Trow var. *ultimum* (MUCL 16164) was developed from the
475 methodology proposed in Toda *et al.* 2015⁴⁸. Plugs of *P. ultimum* were grown at approximately 22°C on
476 potato dextrose agar (PDA) for three days. Infested soil was produced by mixing the surface mycelia
477 from the PDA agar plates into a 5:1 compost:sand mixture (one-90 mm PDA petri per 120 g soil), and
478 incubating the soil at approximately 22°C for three days. Potting mix was composed of 1% (w/w)
479 *Pythium*-infested soil in unsterilised non-infested soil, or 100% unsterilised non-infested soil for a non-
480 infested control. Unsterilised *P. sativum* seeds (Early Onward cultivar) were coated with *B. ambifaria*
481 before planting. *B. ambifaria* coating suspension was produced as follows: an overnight (approximately
482 18 hours) TSB culture of *B. ambifaria* was washed in sterile 1x volume phosphate buffer solution (PBS)
483 and re-suspended in sterile 0.5x volume PBS. The suspension was adjusted to 10x 0.5 OD at 600 nm
484 (approximately 10⁹ cfu/ml), and either applied at the neat concentration or diluted to achieve the desired
485 inoculum levels (10⁸ and 10⁷ cfu/ml). Control *P. sativum* seeds lacking the *B. ambifaria* coating were
486 dipped in PBS. *P. sativum* plants were grown at 22°C with a 16-h light/8-h dark photoperiod (70% RH)
487 for 14 days, and watered as required. Groups of ten seeds per inoculum and seed coat organism were
488 assayed per experiment, and the experiment was performed in triplicate. Significant differences between
489 BCC0191 wild-type and mutant derivatives was assessed using two tailed t-test or Welch's two tailed t-
490 test. Two tailed t-test assumptions were normally distributed data (Shapiro-Wilk test) and equal
491 variances (Bartlett test); Welch's two tailed t-test did not assume equal variances.

492

493 **Metabolite extraction and HPLC analysis**

494 To confirm the absence of cepacin A in the BGC mutants constructed for the different *B. ambifaria* strain
495 backgrounds (BCC0191, BCC1252, BCC1241, BCC0477, BCC1259 and BCC1218; Supplementary
496 Figure 3), each strain was grown on BSM-G agar for three days at 22°C, the bacterial growth removed
497 and an equal amount of agar (a 2 cm disc) extracted with 0.5 ml ethyl acetate for 2 hours at room
498 temperature. This was fractionated on an acetonitrile gradient (5% to 95%) using a Waters®
499 AutoPurification™ HPLC System fitted with a reverse phase analytical column (Waters® XSelect CSH
500 C18, 4.6 x 100 mm, 5 μm). Metabolites eluted from the column were detected by a photodiode array and
501 the peak corresponding to cepacin A identified by its retention time in relation to the LC-MS confirmed
502 presence of the polyne in this fraction.

503

504 ***In vivo* killing assay using *Galleria wax* moth larvae**

505 *Galleria mellonella* wax moth larvae were sourced from BioSystems Technology Ltd TruLarv (Exeter,
506 UK). Bacterial cultures of BCC0191 wild-type and BCC0191Δc3 were grown overnight (approximately 18
507 hours) in TSB broth at 37°C, washed and re-suspended in 1x volume PBS before being adjusted to
508 approximately 1x10⁶ cfu/ml. Larvae were injected in the hindmost proleg on the right-side of the
509 abdomen. Each larva was injected with 10 μl aliquots of *B. ambifaria* BCC0191 wild-type and
510 BCC0191Δc3 bacterial suspensions with a 25G x 1" needle (BD Microlance 3) using a 1705TLL, 50 μL
511 syringe (Hamilton). PBS injections were included as controls. Each condition included ten larvae, and
512 the experiment was performed in triplicate over three days. The larvae were incubated at 37°C for 72
513 hours, and their survival status was monitored at 18, 24, 42, 48, 66 and 72 hours post-inoculation.
514 Larvae were recorded as dead when they failed to respond to physical agitation. The total viable count
515 of the bacterial suspensions was calculated during the first and third replicate via drop-count. The mean
516 average cfu/ml of BCC0191 wild-type and BCC0191Δc3 suspensions were 1.5x10⁶ cfu/ml and 1.0x10⁶
517 cfu/ml, respectively.

518

519 **Murine chronic lung infection model.** A murine respiratory infection model as used for modelling *P.*
520 *aeruginosa* pathogenicity was applied to *B. ambifaria* essentially as described^{19,20}. All experiments were
521 carried out at the University of Liverpool with approval from the UK Home Office and University ethics
522 committee. Randomisation of mice to cages (experimental groups) was performed by animal unit staff
523 with no role in study design as described¹⁹. An initial dosing experiment demonstrated good tolerance of
524 an infectious dose of 10⁶ *B. ambifaria*, equivalent to that used for *P. aeruginosa* in previous studies^{19,20}.
525 Sample size was calculated to give 95% power at alpha 0.05 to detect a >4-fold difference in lung CFU
526 between BCC0191 and BCC0191Δc3, assuming mean CFU of 100 in BCC0191 lung and a standard
527 deviation of 50% of the mean (as determined in preliminary experiments). Groups of 6 mice (female
528 BALB/c, 6-8 weeks old; Charles River, UK) were infected intranasally under anaesthesia
529 (O₂/isofluorane), achieving an actual dose of 2 x 10⁶ *B. ambifaria* BCC0191 or its third chromosome
530 replicon mutant BCC0191Δc3. Symptoms of disease were monitored, and mice culled at 24 hours, 48
531 hours and 5 days post infection. Researchers were not blinded to the experimental groupings. The
532 nasopharyngeal tissue, lungs and spleens were removed, homogenised in 3 ml PBS, serial dilutions
533 prepared and plated onto *Burkholderia cepacia* selective agar (Oxoid, UK) for enumeration of surviving
534 *B. ambifaria*. No animals were excluded from the analysis. Colonies from the tissue of mice carrying
535 infection were confirmed to be strain *B. ambifaria* BCC0191 by Random Amplified Polymorphic DNA
536 typing (RAPD; see Supplementary Figure 8).

537

538 **Rhizocompetence of *B. ambifaria* BCC0191 WT and derivatives**

539 The rhizocompetence of *B. ambifaria* BCC0191 and its derived mutants were evaluated essentially as
540 described⁴⁹. Liquid cultures of BCC0191, BCC0191::ccnJ and BCC0191Δc3 were grown in TSB broth
541 overnight at 37°C (50 μg/ml trimethoprim for BCC0191::ccnJ), then washed and re-suspended in 1x

542 volume PBS and adjusted to 1×10^9 cfu/ml. *Pisum sativum* (pea) seeds were coated in the bacterial
543 suspensions and planted in a potting mix composed of 5:1 multi-purpose compost to sand. The seeds
544 were germinated and grown at 22°C with a 16 hour light - 8 hour dark photoperiod (70% RH) for 14 days
545 and watered as required. After 14 days the plants were removed, and excess soil shaken from the root
546 systems. The 1st – 2nd cm of root was excised, macerated in 1 ml PBS, and serially diluted. Dilutions of
547 the root suspension were plated onto *Burkholderia cepacia* selective agar (BCSA; Oxoid UK) and
548 incubated at 37°C for 24 hours to calculate total viable counts. Three plants were used per strain
549 derivative, and three un-inoculated seeds included as a control. Any growth from the control plants was
550 subject to RAPD PCR profiling to distinguish the bacteria from *B. ambifaria*. Non-*B. ambifaria* growth on
551 the control plates was discounted from the total viable counts. Total viable counts were standardised to
552 1 g fresh weight of root.

553

554

555 **Data Availability**

556 Sequence data that support the genomic findings of this study have been deposited in the European
557 Nucleotide Archive with the accession/bioproject codes listed in Supplementary Table 1. The data that
558 support the antimicrobial production, *P. sativum* and *G. mellonella* survival, and murine infection model
559 findings of this study are available from the corresponding authors upon request. Bacterial strains and
560 constructs will be made available upon written request to the corresponding authors and after signing a
561 Material Transfer Agreement. We are restricted in re-distributing certain bacterial strains such as those
562 from recognised culture collections, but such requests will be re-directed to the appropriate source.

563

564 **Code Availability**

565 The publicly available software and codes used for genome sequence determination, phylogenomics,
566 mass spectrometry and general statistical analysis are described in the appropriate Method sections.

567

568 **Correspondence:**

569 Please address correspondence to: Eshwar Mahenthiralingam; email: MahenthiralingamE@cardiff.ac.uk
570 or Alex J. Mullins, email: MullinsA@cardiff.ac.uk. Requests for materials should be addressed to Eshwar
571 Mahenthiralingam.

572

573 **Acknowledgements:**

574 AM is funded by a Biotechnology and Biological Sciences Research Council (BBSRC) South West
575 doctoral training partnership award (BY1910 7007). EM, GC, TC and JP acknowledge additional support
576 for genome mining from BBSRC award BB/L021692/1; CJ and MJ were funded by this award. M.J is
577 currently the recipient of a BBSRC Future Leader Fellowship (BB/R01212/1). The Bruker maXis II
578 UHPLC-ESI-Q-TOF-MS system used in this research was funded by the BBSRC (BB/M017982/1). GW
579 was supported by awards to EM from the Life Sciences Bridging Fund and Wellcome Trust Institutional

580 Strategic Support Fund held at Cardiff University. TRC and MB acknowledge funding support from the
581 Medical Research Council's Cloud Infrastructure for Microbial Bioinformatics (MR/L015080/1) which
582 provided the computational resources to undertake the analyses for this work. DN and AG acknowledge
583 funding from a Wellcome Trust and Royal Society Sir Henry Dale Fellowship awarded to DN (Grant
584 Number 204457/Z/16/Z). GC is the recipient of a Wolfson Research Merit Award from the Royal Society
585 (WM130033). We thank Leo Eberl and Kirsty Agnoli for provision of mini-c3 used for third replicon
586 deletion.

587

588 **Author contributions:**

589 The initial study to characterise the genomes of *B. ambifaria* as a biopesticide was conceived by EM,
590 with additional aspects of the study design added by AM, GC and JM. AM performed all aspects of the
591 study with the exception of the LC-MS profiling, and was assisted by specific contributions from the
592 following: datasets and input for genome sequencing and mining, EM, GC, JP and TC; genome
593 assembly, phylogenomics, cluster mining and de-replication, MB; LuxR mining, EM; generation of a
594 cepacin insertional mutant and antimicrobial activity screening, CJ; extraction, identification and
595 fractionation of *Burkholderia* metabolites by HPLC, and enacyloxin MIC analysis, GW; LC-MS
596 identification and confirmation of *B. ambifaria* antimicrobial metabolites, MJ and GC; biocontrol
597 modelling EM, GW, and JM; evaluation and analysis of plant models, JM; *Galleria* virulence assays, GW
598 and CJ; and murine infection modelling and analysis, AG and DN. AM and EM developed the first draft
599 of the manuscript and all authors read and contributed towards finalisation of the study.

600

601

602 **Competing interests:**

603 The authors do not have any competing interest to declare.

604 **Table 1. Correlation of BGC presence and *in vitro* metabolite production in *B. ambifaria*¹**

<i>B. ambifaria</i> strain (clade)	Pyrrolnitrin		Burkholdines		Hydroxyquinolines		Bactobolins		Enacyloxin IIa		Cepacins ²	
	BGC	Metabolite	BGC	Metabolite	BGC	Metabolite	BGC	Metabolite	BGC	Metabolite	BGC	Metabolite
Characterised biocontrol strains												
ATCC 53267 / BCC0284 (1d)	+	+	+	+	-	-	-	-	-	-	-	-
ATCC 53266 / BCC0338 (1d)	+	-	+	-	-	-	-	-	-	-	-	-
BC-F / BCC0203 (1b)	+	+	+	+	-	-	+	+	+	+	-	-
AMMD / BCC0207 (1b)	+	+	+	+	+	-	-	-	+	+	-	-
Ral-3 / BCC0192 (2)	+	+	-	-	+	+	+	+	-	-	+	-
J82 / BCC0191 (3)	+	+	+	+	-	-	-	-	-	-	+	+
M54 / BCC0316 (3)	+	+	+	+	-	-	-	-	-	-	+	+
Other strains:												
BCC1100 (1a)	+	+	+	+	-	-	+	+	-	-	-	-
BCC1105 (1c)	+	+	-	-	-	-	-	-	-	-	-	-
BCC1220 (2)	+	+	-	-	+	+	-	-	-	-	+	-

605

606 Footnotes:

607 ¹Grey cells highlight BGCs in specific strains where the corresponding metabolite was not detected.

608 ²The metabolite cepacin was detected prior to identification of its biosynthetic gene cluster.

609 **Figure legends**

610

611 **Figure 1. Core-gene phylogeny of 64 *B. ambifaria* strains (a) aligned with presence/absence grid of known**
612 **antimicrobial specialized metabolite BGCs (b) and antimicrobial activity heatmap (c). (a)** The phylogenetic
613 tree was constructed based on 3784 core genes identified and aligned using the software Roary. The root was
614 determined using a secondary tree containing an outgroup species, *Burkholderia vietnamiensis* G4
615 (Supplementary Figure 10). Six clades were defined in the phylogeny, however, strains BCC1066 and MEX-5
616 branched outside these clades. Strains subject to further LC-MS analysis are highlighted in **bold**; strains with
617 historical biocontrol usage are indicated with an asterisk. RAxML was used to construct the maximum-likelihood
618 phylogeny using the generalised time reversible (GTR) model with a GAMMA substitution (100 bootstraps). Nodes
619 with bootstrap values <70% are indicated with black circles. The evolutionary distance scale bar represents the
620 number of base substitutions per site. **(b)** The presence of the eight characterised anti-fungal and antibiotic gene
621 clusters: pyrrolnitrin, burkholdine, AFC-BC11, hydroxyquinolines, cepacin A, bactobolins, phenazine and
622 enacyloxin IIa in the 64 *B. ambifaria* strains are ordered by phylogenetic position. Matrix generated using
623 Phandango⁵⁰. **(c)** The antimicrobial activity of 62 *B. ambifaria* strains were defined by measuring the diameter of
624 the zones of inhibition (mm); $n = 2$ overlays of each *B. ambifaria* strain against each susceptibility organism.
625 Heatmap shows mean zone of inhibition. Strains MEX-5 and IOP40-10 were not available for the antimicrobial
626 production assay.

627

628 **Figure 2. Specialized metabolite BGC network analysis of 64 *B. ambifaria* strains.** A total of 1,272 BGCs were
629 detected across the 64 strains, and dereplication indicated these represented 38 distinct BGCs (38 distinct network
630 clusters). Nucleotide sequences were clustered using Mash and visualized with Cytoscape. This network analysis
631 was used to provide a visual summary of the breadth of *B. ambifaria* BGCs including their biosynthetic diversity,
632 strain distribution, and core or accessory nature within the species. Each node represents a specialized metabolite
633 BGC extracted from a single *B. ambifaria* strain. Node colours represent specialized metabolite classes, and
634 numbers correspond to the number BGC examples (nodes) of each distinct BGC (network cluster). Core BGCs
635 were defined as BGCs that occurred in >98% of *B. ambifaria* strains. Characterised BGCs known in the literature
636 are labelled. BGCs responsible for pyrrolnitrin, AFC-BC11 and hydroxyquinolines biosynthesis are classified as
637 Other (O) by antiSMASH but represent different metabolite classes not recognised by antiSMASH.

638

639 **Figure 3. Unrooted phylogeny of LuxR protein homologues extracted from 64 *B. ambifaria* strains.**
640 Branches were labelled with characterised quorum sensing systems or putative/confirmed LuxR regulatory
641 functions based on the literature and annotated flanking genes starting within 5 kbp upstream and/or downstream
642 of the *luxR* gene. The number of strains encoding distinct LuxR homologues is indicated in brackets. A total of 356
643 homologues were identified across the 64 strains, representing 14 distinct LuxR protein clades. FastTree was used
644 to construct the approximate-maximum-likelihood phylogeny using the generalised time reversible substitution
645 model. The evolutionary distance scale bar represents the number of base substitutions per site.

646

647 **Figure 4. Organization of the cepacin A biosynthetic gene cluster, LC-MS analysis of cepacin A production**
648 **and antimicrobial screening of *B. ambifaria* BCC0191 wild-type (WT) and cepacin A deficient derivative**
649 **(::*ccnJ*). (a)** Organisation and putative function of genes within the cepacin A BGC; further annotation details are
650 provided in Supplementary Figure 9. The insertion site of the vector used during mutagenesis is highlighted by the

651 inverted yellow triangle. **(b)** Zones of inhibition against *S. aureus* NCTC 12981, *P. carotovorum* LMG 2464 and *P.*
652 *ultimum* Trow var. *ultimum* MUCL 16164 by BCC0191 WT and BCC0191::ccnJ. Scale bar represents 20 mm. *n* = 3
653 biological replicates. Images were converted to greyscale, brightness decreased by 20%, and contrast increased
654 by 20%. **(c)** Extracted ion chromatograms at *m/z* = 293.08 ± 0.02, corresponding to [M + Na]⁺ for cepacin A, from
655 LC-MS analyses of crude extracts from agar-grown cultures of BCC0191 WT (top) and the BCC0191::ccnJ mutant
656 (bottom); *n* = 3 independent LC-MS analyses of WT and mutant cultures. **(d)** Structure of cepacin A, the identity of
657 which was confirmed by comparison to an authentic standard from a known producer (Supplementary Figure 3).

658

659 **Figure 5. Biological control of *Pythium* damping-off disease is mediated by *B. ambifaria* cepacin. (a)** Pea
660 germination (14 days) in *P. ultimum* infested soil observed for groups of 10 seeds coated with 10⁷, 10⁶ and 10⁵ cfu,
661 respectively, of BCC0191 wild-type (WT) and BCC0191::ccnJ. The overall percentage survival of germinating peas
662 treated with the WT and BCC0191::ccnJ *B. ambifaria* strains is shown on the right of panel A. Survival was
663 assessed as plants that had stems >30 mm in height after 14 days. Plant survival was significantly different at
664 every inoculum level between BCC0191 WT and BCC0191::ccnJ, as indicated by two-sided t-test or Welch's two-
665 sided t-test (* = *p* < 0.05; ** = *p* < 0.01); significant difference (left to right) *p* = 0.002, *p* = 0.03, *p* = 0.002 with 95%
666 confidence interval. *n* = 10 seeds per condition (seed coat) and dosage (cfu/seed), repeated in triplicate. Centre
667 bar represents mean, and error bars represent standard error. **(b)** Pea germination (14 days) in *P. ultimum* infested
668 soil observed for groups of 10 seeds coated with 10⁷, 10⁶ and 10⁵ cfu, respectively, of BCC0191 WT and
669 BCC0191Δc3. The overall percentage survival of germinating peas treated with BCC0191 WT and BCC0191Δc3 is
670 shown on the right of panel B. No significant difference (left to right: *p* = 0.22, *p* = 0.22, *p* = 0.16), as determined by
671 two-sided t-test with 95% confidence interval, in plant survival between BCC0191 WT and BCC0191Δc3 at all
672 inoculum levels. *n* = 10 seeds per condition (seed coat) and dosage (cfu/seed), repeated in triplicate. Centre bar
673 represents mean, and error bars represent standard error.

674

675 **References:**


676

- 677 1. Depoorter, E. *et al.* *Burkholderia*: an update on taxonomy and biotechnological potential as
678 antibiotic producers. *Appl. Microbiol. Biotechnol.* **100**, 5215–5229 (2016).
- 679 2. Parke, J. L. & Gurian-Sherman, D. Diversity of the *Burkholderia cepacia* complex and implications
680 for risk assessment of biological control strains. *Annu. Rev. Phytopathol.* **39**, 225–258 (2001).
- 681 3. Mahenthiralingam, E. *et al.* Enacyloxins are products of an unusual hybrid modular polyketide
682 synthase encoded by a cryptic *Burkholderia ambifaria* genomic island. *Chem. Biol.* **18**, 665–677
683 (2011).
- 684 4. Masschelein, J., Jenner, M. & Challis, G. L. Antibiotics from Gram-negative bacteria: a
685 comprehensive overview and selected biosynthetic highlights. *Nat. Prod. Rep.* **34**, 712–783
686 (2017).
- 687 5. Seyedsayamdost, M. R. *et al.* Quorum-sensing-regulated bactobolin production by *Burkholderia*
688 *thailandensis* E264. *Org. Lett.* **12**, 716–719 (2010).
- 689 6. Song, L. *et al.* Discovery and biosynthesis of gladiolin: A *Burkholderia gladioli* antibiotic with
690 promising activity against *Mycobacterium tuberculosis*. *J. Am. Chem. Soc.* **139**, jacs.7b03382



- 691 (2017).
- 692 7. Flórez, L. V. *et al.* Antibiotic-producing symbionts dynamically transition between plant
693 pathogenicity and insect-defensive mutualism. *Nat. Commun.* **8**, 15172 (2017).
- 694 8. Kim, J. *et al.* Quorum sensing and the LysR-type transcriptional activator ToxR regulate toxoflavin
695 biosynthesis and transport in *Burkholderia glumae*. *Mol. Microbiol.* **54**, 921–934 (2004).
- 696 9. Ross, C., Scherlach, K., Kloss, F. & Hertweck, C. The molecular basis of conjugated polyene
697 biosynthesis in phytopathogenic bacteria. *Angew. Chemie - Int. Ed.* **53**, 7794–7798 (2014).
- 698 10. Mansfield, J. *et al.* Top 10 plant pathogenic bacteria in molecular plant pathology. *Mol. Plant*
699 *Pathol.* **13**, 614–629 (2012).
- 700 11. Howden, A. J. M., Rico, A., Mentlak, T., Miguet, L. & Preston, G. M. *Pseudomonas syringae* pv.
701 *syringae* B728a hydrolyses indole-3-acetonitrile to the plant hormone indole-3-acetic acid. *Mol.*
702 *Plant Pathol.* **10**, 857–865 (2009).
- 703 12. Agnoli, K. *et al.* Exposing the third chromosome of *Burkholderia cepacia* complex strains as a
704 virulence plasmid. *Mol. Microbiol.* **83**, 362–378 (2012).
- 705 13. Schmidt, S. *et al.* Production of the antifungal compound pyrrolnitrin is quorum sensing-regulated
706 in members of the *Burkholderia cepacia* complex. *Environ. Microbiol.* **11**, 1422–1437 (2009).
- 707 14. Tawfik, K. A. *et al.* Burkholdines 1097 and 1229, potent antifungal peptides from *Burkholderia*
708 *ambifaria* 2.2N. *Org. Lett.* **12**, 664–666 (2010).
- 709 15. Hareland, W. A., Crawford, R. L., Chapman, P. J. & Dagley, S. Metabolic function and properties
710 of 4-hydroxyphenylacetic acid 1-hydroxylase from *Pseudomonas acidovorans*. *J. Bacteriol.* **121**,
711 272–85 (1975).
- 712 16. Parker, W. L. *et al.* Cepacin A and cepacin B, two new antibiotics produced by *Pseudomonas*
713 *cepacia*. *J. Antibiot. (Tokyo)*. **37**, 431–440 (1984).
- 714 17. Weber, T. *et al.* antiSMASH 3.0—a comprehensive resource for the genome mining of biosynthetic
715 gene clusters. *Nucleic Acids Res.* **43**, W237–43 (2015).
- 716 18. Ishida, K., Lincke, T., Behnken, S. & Hertweck, C. Induced Biosynthesis of Cryptic Polyketide
717 Metabolites in a *Burkholderia thailandensis* Quorum Sensing Mutant. *J. Am. Chem. Soc.* **132**,
718 13966–13968 (2010).
- 719 19. Fothergill, J. L., Neill, D. R., Loman, N., Winstanley, C. & Kadioglu, A. *Pseudomonas aeruginosa*
720 adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs. *Nat.*
721 *Commun.* **5**, 4780 (2014).
- 722 20. Bricio-Moreno, L. *et al.* Evolutionary trade-offs associated with loss of PmrB function in host-
723 adapted *Pseudomonas aeruginosa*. *Nat. Commun.* **9**, 2635 (2018).
- 724 21. Duerkop, B. A. *et al.* Quorum-sensing control of antibiotic synthesis in *Burkholderia thailandensis*.
725 *J. Bacteriol.* **191**, 3909–3918 (2009).
- 726 22. Lee, J. & Zhang, L. The hierarchy quorum sensing network in *Pseudomonas aeruginosa*. *Protein*
727 *Cell* **6**, 26–41 (2015).
- 728 23. Yabuuchi, E. *et al.* Proposal of *Burkholderia* gen. nov. and transfer of seven species of the genus
729 *Pseudomonas* homology group II to the new genus, with the type species *Burkholderia cepacia*


- 730 (Palleroni and Holmes 1981) comb. nov. *Microbiol. Immunol.* **36**, 1251–75 (1992).
- 731 24. Vanlaere, E. *et al.* *Burkholderia latens* sp. nov., *Burkholderia diffusa* sp. nov., *Burkholderia arboris*
732 sp. nov., *Burkholderia seminalis* sp. nov. and *Burkholderia metallica* sp. nov., novel species within
733 the *Burkholderia cepacia* comple. *Int. J. Syst. Evol. Microbiol.* **58**, 1580–1590 (2008).
- 734 25. Fritsche, K. *et al.* Biosynthetic genes and activity spectrum of antifungal polyynes from *Collimonas*
735 *fungivorans* Ter331. *Environ. Microbiol.* **16**, 1334–1345 (2014).
- 736 26. Kai, K., Sogame, M., Sakurai, F., Nasu, N. & Fujita, M. Collimonins A–D, Unstable Polyynes with
737 Antifungal or Pigmentation Activities from the Fungus-Feeding Bacterium *Collimonas fungivorans*
738 Ter331. *Org. Lett.* **20**, 3536–3540 (2018).
- 739 27. Haas, D. & Keel, C. Regulation of antibiotic production in root-colonizing *Pseudomonas* spp. And
740 relevance for biological control of plant disease. *Annu. Rev. Phytopathol.* **41**, 117–153 (2003).
- 741 28. Palazzini, J. M., Dunlap, C. A., Bowman, M. J. & Chulze, S. N. *Bacillus velezensis* RC 218 as a
742 biocontrol agent to reduce Fusarium head blight and deoxynivalenol accumulation: Genome
743 sequencing and secondary metabolite cluster profiles. *Microbiol. Res.* **192**, 30–36 (2016).
- 744 29. Law, J. W.-F. *et al.* The potential of *Streptomyces* as biocontrol agents against the Rice Blast
745 Fungus, *Magnaporthe oryzae* (*Pyricularia oryzae*). *Front. Microbiol.* **8**, 3 (2017).
- 746 30. Eberl, L. & Vandamme, P. Members of the genus *Burkholderia*: good and bad guys.
747 *F1000Research* **5**, (2016).
- 748 31. LiPuma, J. J. The Changing Microbial Epidemiology in Cystic Fibrosis. *Clin. Microbiol. Rev.* **23**,
749 299–323 (2010).
- 750 32. Kenna, D. T. D. *et al.* Prevalence of *Burkholderia* species, including members of *Burkholderia*
751 *cepacia* complex, among UK cystic and non-cystic fibrosis patients. *J. Med. Microbiol.* **66**, 490–
752 501 (2017).
- 753 33. Galardini, M., Biondi, E. G., Bazzicalupo, M. & Mengoni, A. CONTIGuator: a bacterial genomes
754 finishing tool for structural insights on draft genomes. *Source Code Biol. Med.* **6**, 11 (2011).
- 755 34. Li, H. Circlator: automated circularization of genome assemblies using long sequencing reads. **16**,
756 (2013).
- 757 35. Pritchard, L. *et al.* Genomics and taxonomy in diagnostics for food security: soft-rotting
758 enterobacterial plant pathogens. *Anal. Methods* **8**, 12–24 (2016).
- 759 36. Richter, M. & Rossello-Mora, R. Shifting the genomic gold standard for the prokaryotic species
760 definition. *Proc. Natl. Acad. Sci.* **106**, 19126–19131 (2009).
- 761 37. Connor, T. R. *et al.* CLIMB (the Cloud Infrastructure for Microbial Bioinformatics): an online
762 resource for the medical microbiology community. *Microb. Genomics* **2**, (2016).
- 763 38. Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* **30**, 2068–2069 (2014).
- 764 39. Morgulis, A. *et al.* BLAST+: architecture and applications. *Bioinformatics* **24**, 1757–1764 (2008).
- 765 40. Ondov, B. D. *et al.* Mash: fast genome and metagenome distance estimation using MinHash.
766 *Genome Biol.* **17**, 132 (2016).
- 767 41. Shannon, P. *et al.* Cytoscape: A software environment for integrated models of biomolecular
768 interaction networks. *Genome Res.* **13**, 2498–2504 (2003).

- 769 42. Page, A. J. *et al.* Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics* **31**,
770 3691–3693 (2015).
- 771 43. Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2 - Approximately maximum-likelihood trees for
772 large alignments. *PLoS One* **5**, e9490 (2010).
- 773 44. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large
774 phylogenies. *Bioinformatics* **30**, 1312–3 (2014).
- 775 45. Flanagan, R. S., Aubert, D., Kooi, C., Sokol, P. A. & Valvano, M. A. *Burkholderia cenocepacia*
776 requires a periplasmic HtrA protease for growth under thermal and osmotic stress and for survival
777 *in vivo*. *Infect. Immun.* **75**, 1679–1689 (2007).
- 778 46. Gan, H. M. *et al.* Whole genome sequencing and analysis reveal insights into the genetic
779 structure, diversity and evolutionary relatedness of *luxI* and *luxR* homologs in bacteria belonging
780 to the Sphingomonadaceae family. *Front. Cell. Infect. Microbiol.* **4**, 188 (2014).
- 781 47. Katoh, K., Misawa, K., Kuma, K. & Miyata, T. MAFFT: a novel method for rapid multiple sequence
782 alignment based on fast Fourier transform. *Nucleic Acids Res.* **30**, 3059–66 (2002).
- 783 48. Toda, T., Iwasa, A., Fuji, S. & Furuya, H. Widespread occurrence of *Pythium arrhenomanes*
784 pathogenic to rice seedlings around Japanese rice fields. *Plant Dis.* **99**, 1823–1831 (2015).
- 785 49. Vidal-Quist, J. C. *et al.* *Arabidopsis thaliana* and *Pisum sativum* models demonstrate that root
786 colonization is an intrinsic trait of *Burkholderia cepacia* complex bacteria. *Microbiology* **160**, 373–
787 384 (2014).
- 788 50. Hadfield, J. *et al.* Phandango: an interactive viewer for bacterial population genomics.
789 *Bioinformatics* **34**, 292–293 (2018).
- 790





Core Specialised Metabolite BGCs





a) *B. ambifaria* WT vs *::ccnJ*



b) *B. ambifaria* WT vs $\Delta c3$

